The small volume parenteral market size has grown strongly in recent years. It will grow from $191.36 billion in 2025 to $207.18 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing use of injectable therapies, expansion of hospital-based drug administration, availability of glass ampule packaging, growth of acute care treatments, rising demand for parenteral nutrition.
The small volume parenteral market size is expected to see strong growth in the next few years. It will grow to $275.99 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing demand for biologics and vaccines, rising adoption of self-injectable therapies, expansion of aseptic manufacturing capacity, growing focus on advanced drug delivery systems, increasing investments in sterile packaging technologies. Major trends in the forecast period include increasing adoption of prefilled syringe formats, rising demand for sterile injectable drugs, growing use of single-dose parenterals, expansion of vaccine and biologic administration, enhanced focus on drug safety and stability.
The increasing number of surgeries is expected to drive the growth of the small-volume parenteral market going forward. Surgery is a medical specialty that involves operative techniques to investigate or treat pathological conditions, improve bodily function or appearance, or repair damaged areas. The rising rate of surgeries, fueled by advancements in medical technology and an aging population, is increasing demand for surgical interventions. Small-volume parenteral solutions are used in surgeries to deliver medications, electrolytes, and nutrients directly into the bloodstream with precision. For instance, in June 2024, according to the American Society of Plastic Surgeons, a US-based non-profit organization, minimally invasive procedures increased by 7% in 2023, exceeding the overall growth rate of surgical procedures by 2%. Hand surgeries such as carpal tunnel, arthritis, and trigger finger totaled 207,887 procedures, marking a 2% increase from 2022. Therefore, the rising number of surgeries is propelling the growth of the small-volume parenteral market.
Major companies in the small-volume parenteral market are increasingly developing prefilled, ready-to-use injectable formulations to improve dosing precision, minimize contamination risk, and enhance patient safety. Prefilled, ready-to-use injectables are medications supplied in a sterile syringe or vial, allowing direct administration without additional preparation. For instance, in June 2025, Gland Pharma Limited, an India-based pharmaceutical company specializing in generic injectables, received USFDA approval for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection 2.5 mg/mL. This injection is indicated for rapidly raising blood pressure in adults with septic or distributive shock when standard therapies are insufficient. It works by binding to vascular smooth muscle receptors, causing vasoconstriction and stimulating aldosterone release, with a rapid onset that typically achieves target blood pressure within five minutes. Administered intravenously, the dosage is carefully titrated to maintain desired blood pressure, providing critical support to patients who remain hypotensive despite fluid resuscitation and vasopressor therapy.
In February 2024, Eris Lifesciences Ltd., a pharmaceutical firm headquartered in India, acquired a majority stake of 51% in Swiss Parenteral for $76.52 million. This strategic move by Eris enhances its footprint in the sterile injectables sector and aligns with its strategy of targeting emerging markets. Swiss Parenteral, also based in India, specializes in the production of small-volume liquid parenteral formulations within the pharmaceutical industry.
Major companies operating in the small volume parenteral market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Viatris Inc, Intas Pharmaceuticals Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Alembic Pharmaceuticals Ltd., Wockhardt Ltd.
North America was the largest region in the small volume parenteral market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small volume parenteral market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the small volume parenteral market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the small volume parenteral market by increasing costs of imported glass vials, ampules, elastomeric closures, sterile filling equipment, and pharmaceutical-grade raw materials. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported packaging and processing equipment, while Asia-Pacific faces cost pressures on export-oriented production. These tariffs are raising manufacturing costs and influencing drug pricing strategies. However, they are also encouraging domestic vial manufacturing, local aseptic filling capacity expansion, and investments in advanced injectable drug production infrastructure.
The small volume parenteral market research report is one of a series of new reports that provides small volume parenteral market statistics, including small volume parenteral industry global market size, regional shares, competitors with a small volume parenteral market share, detailed small volume parenteral market segments, market trends and opportunities, and any further data you may need to thrive in the small volume parenteral industry. This small volume parenteral market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Small volume parenteral (SVP) relates to a classification of sterile pharmaceuticals designed for parenteral delivery (circumventing the gastrointestinal tract) and usually dispensed in volumes of 100 milliliters (mL) or smaller. These items serve diverse medical functions, such as administering medications, vaccines, or biological therapies directly into the body via intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes.
The primary categories of small volume parenteral include ampules, vials, and prefilled syringes. Ampules are compact, sealed containers utilized for storing and protecting liquid medications, typically opened by breaking off the neck. Available in single or multiple doses, they are employed to address diverse conditions such as pain management, cancer treatment, malnutrition, gastrointestinal issues, diabetes, among others. Widely used in local anesthetics, vaccines, and similar applications, they cater to various end users including hospitals, clinics, ambulatory surgical centers, and others.
The small volume parenteral market consists of sales of epinephrine, insulin, heparin, morphine, and vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The small volume parenteral market size is expected to see strong growth in the next few years. It will grow to $275.99 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing demand for biologics and vaccines, rising adoption of self-injectable therapies, expansion of aseptic manufacturing capacity, growing focus on advanced drug delivery systems, increasing investments in sterile packaging technologies. Major trends in the forecast period include increasing adoption of prefilled syringe formats, rising demand for sterile injectable drugs, growing use of single-dose parenterals, expansion of vaccine and biologic administration, enhanced focus on drug safety and stability.
The increasing number of surgeries is expected to drive the growth of the small-volume parenteral market going forward. Surgery is a medical specialty that involves operative techniques to investigate or treat pathological conditions, improve bodily function or appearance, or repair damaged areas. The rising rate of surgeries, fueled by advancements in medical technology and an aging population, is increasing demand for surgical interventions. Small-volume parenteral solutions are used in surgeries to deliver medications, electrolytes, and nutrients directly into the bloodstream with precision. For instance, in June 2024, according to the American Society of Plastic Surgeons, a US-based non-profit organization, minimally invasive procedures increased by 7% in 2023, exceeding the overall growth rate of surgical procedures by 2%. Hand surgeries such as carpal tunnel, arthritis, and trigger finger totaled 207,887 procedures, marking a 2% increase from 2022. Therefore, the rising number of surgeries is propelling the growth of the small-volume parenteral market.
Major companies in the small-volume parenteral market are increasingly developing prefilled, ready-to-use injectable formulations to improve dosing precision, minimize contamination risk, and enhance patient safety. Prefilled, ready-to-use injectables are medications supplied in a sterile syringe or vial, allowing direct administration without additional preparation. For instance, in June 2025, Gland Pharma Limited, an India-based pharmaceutical company specializing in generic injectables, received USFDA approval for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection 2.5 mg/mL. This injection is indicated for rapidly raising blood pressure in adults with septic or distributive shock when standard therapies are insufficient. It works by binding to vascular smooth muscle receptors, causing vasoconstriction and stimulating aldosterone release, with a rapid onset that typically achieves target blood pressure within five minutes. Administered intravenously, the dosage is carefully titrated to maintain desired blood pressure, providing critical support to patients who remain hypotensive despite fluid resuscitation and vasopressor therapy.
In February 2024, Eris Lifesciences Ltd., a pharmaceutical firm headquartered in India, acquired a majority stake of 51% in Swiss Parenteral for $76.52 million. This strategic move by Eris enhances its footprint in the sterile injectables sector and aligns with its strategy of targeting emerging markets. Swiss Parenteral, also based in India, specializes in the production of small-volume liquid parenteral formulations within the pharmaceutical industry.
Major companies operating in the small volume parenteral market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Viatris Inc, Intas Pharmaceuticals Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Alembic Pharmaceuticals Ltd., Wockhardt Ltd.
North America was the largest region in the small volume parenteral market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small volume parenteral market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the small volume parenteral market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the small volume parenteral market by increasing costs of imported glass vials, ampules, elastomeric closures, sterile filling equipment, and pharmaceutical-grade raw materials. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported packaging and processing equipment, while Asia-Pacific faces cost pressures on export-oriented production. These tariffs are raising manufacturing costs and influencing drug pricing strategies. However, they are also encouraging domestic vial manufacturing, local aseptic filling capacity expansion, and investments in advanced injectable drug production infrastructure.
The small volume parenteral market research report is one of a series of new reports that provides small volume parenteral market statistics, including small volume parenteral industry global market size, regional shares, competitors with a small volume parenteral market share, detailed small volume parenteral market segments, market trends and opportunities, and any further data you may need to thrive in the small volume parenteral industry. This small volume parenteral market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Small volume parenteral (SVP) relates to a classification of sterile pharmaceuticals designed for parenteral delivery (circumventing the gastrointestinal tract) and usually dispensed in volumes of 100 milliliters (mL) or smaller. These items serve diverse medical functions, such as administering medications, vaccines, or biological therapies directly into the body via intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes.
The primary categories of small volume parenteral include ampules, vials, and prefilled syringes. Ampules are compact, sealed containers utilized for storing and protecting liquid medications, typically opened by breaking off the neck. Available in single or multiple doses, they are employed to address diverse conditions such as pain management, cancer treatment, malnutrition, gastrointestinal issues, diabetes, among others. Widely used in local anesthetics, vaccines, and similar applications, they cater to various end users including hospitals, clinics, ambulatory surgical centers, and others.
The small volume parenteral market consists of sales of epinephrine, insulin, heparin, morphine, and vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Small Volume Parenteral Market Characteristics
3. Small Volume Parenteral Market Supply Chain Analysis
4. Global Small Volume Parenteral Market Trends and Strategies
5. Small Volume Parenteral Market Analysis of End Use Industries
7. Global Small Volume Parenteral Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Small Volume Parenteral Total Addressable Market (TAM) Analysis for the Market
9. Small Volume Parenteral Market Segmentation
10. Small Volume Parenteral Market Regional and Country Analysis
11. Asia-Pacific Small Volume Parenteral Market
12. China Small Volume Parenteral Market
13. India Small Volume Parenteral Market
14. Japan Small Volume Parenteral Market
15. Australia Small Volume Parenteral Market
16. Indonesia Small Volume Parenteral Market
17. South Korea Small Volume Parenteral Market
18. Taiwan Small Volume Parenteral Market
19. South East Asia Small Volume Parenteral Market
20. Western Europe Small Volume Parenteral Market
21. UK Small Volume Parenteral Market
22. Germany Small Volume Parenteral Market
23. France Small Volume Parenteral Market
24. Italy Small Volume Parenteral Market
25. Spain Small Volume Parenteral Market
26. Eastern Europe Small Volume Parenteral Market
27. Russia Small Volume Parenteral Market
28. North America Small Volume Parenteral Market
29. USA Small Volume Parenteral Market
30. Canada Small Volume Parenteral Market
31. South America Small Volume Parenteral Market
32. Brazil Small Volume Parenteral Market
33. Middle East Small Volume Parenteral Market
34. Africa Small Volume Parenteral Market
36. Small Volume Parenteral Market Competitive Landscape and Company Profiles
37. Small Volume Parenteral Market Other Major and Innovative Companies
40. Small Volume Parenteral Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Small Volume Parenteral Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses small volume parenteral market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for small volume parenteral? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small volume parenteral market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Ampules; Vials; Prefilled Syringes2) By Dose Type: Single Dose; Multiple Dose
3) By Indication Type: Pain Management; Cancer Care; Malnourishment; Gastrointestinal Disorders; Diabetes; Other Indications
4) By Application: Local Anesthetics; Vaccines; Other Applications
5) By End User: Hospitals; Clinics; Ambulatory Surgical Center; Other End Users
Subsegments:
1) By Ampules: Glass Ampules; Plastic Ampules2) By Vials: Glass Vials; Plastic Vials; Single-dose Vials; Multi-dose Vials
3) By Prefilled Syringes: Glass Prefilled Syringes; Plastic Prefilled Syringes
Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Sun Pharmaceutical Industries Ltd.; Boehringer Ingelheim GmbH; Viatris Inc; Intas Pharmaceuticals Ltd.; Aurobindo Pharma Limited; Dr. Reddy’s Laboratories Ltd.; Cipla Limited; Hikma Pharmaceuticals PLC; Lupin Limited; Biocon Limited; Torrent Pharmaceuticals Ltd.; Zydus Cadila; Alembic Pharmaceuticals Ltd.; Wockhardt Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Small Volume Parenteral market report include:- Pfizer Inc.
- AbbVie Inc.
- Bayer AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Novartis AG
- GlaxoSmithKline plc
- Eli Lilly and Company
- Baxter International Inc.
- Teva Pharmaceutical Industries Ltd.
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Boehringer Ingelheim GmbH
- Viatris Inc
- Intas Pharmaceuticals Ltd.
- Aurobindo Pharma Limited
- Dr. Reddy’s Laboratories Ltd.
- Cipla Limited
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Biocon Limited
- Torrent Pharmaceuticals Ltd.
- Zydus Cadila
- Alembic Pharmaceuticals Ltd.
- Wockhardt Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 207.18 Billion |
| Forecasted Market Value ( USD | $ 275.99 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
